April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study and failed to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 01, 2025 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics is facing a class action lawsuit alleging securities fraud, with potential financial and reputational implications from discontinuing its NTLA-3001 research program.
The lawsuit and research discontinuation suggest significant operational challenges, potential financial penalties, and loss of investor confidence, which could negatively impact NTLA's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100